Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. Issue 6 (1st June 2002)

• Record Type: Journal Article
• Authors: Solfrizzi, V; Panza, F; D'Introno, A; Colacicco, A M; Capurso, C; Basile, A M; Capurso, A
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 72:Issue 6(2002)
• Page Start: 732
• Page End: 736
• Publication Date: 2002-06-01
• Subjects: Lp(a) lipoprotein -- apolipoprotein E -- total cholesterol -- Alzheimer's disease; AD, Alzheimer's disease -- LDL, low density lipoprotein -- Lp(a), lipoprotein(a) -- OR, odds ratio -- TC, total cholesterol; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp.72.6.732
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objectives: To explore the possible role of serum lipoprotein(a) (Lp(a)), apolipoprotein E polymorphism, and total cholesterol (TC) serum concentrations in Alzheimer's disease (AD). Methods: Lp(a) serum concentrations, apolipoprotein E genotypes, and TC serum concentrations were determined in 61 patients with a diagnosis of probable AD and in 63 healthy unrelated age matched controls. Genomic DNA was obtained and amplified by polymerase chain reaction and apolipoprotein E genotypes were defined following a previously described procedure. Results: Lp(a) serum concentrations were significantly associated in a non-linear relation with an increased risk for AD, independently of apolipoprotein E genotypes and sex and dependent on age (truth association) and TC serum concentrations (spurious association). The effect of age adjusted for TC on the odds of having AD increased non-linearly with increasing Lp(a) serum concentrations, with a plateau between 70 and 355 mg/l (odds ratio 11.33). For Lp(a) serum concentrations ≥ 360 mg/l, the effect of age (≥ 72 years) was associated with a reduction in odds of having AD (odds ratio 0.15). Conclusion: It is suggested that increased Lp(a) serum concentrations, by increasing the risk for cerebrovascular disease, may have a role in determining clinical AD.